Prot #MVT-601-050: A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women with Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy